

DAFTAR PUSTAKA

1. Mendis S, Puska P, Norrving B. *Global atlas on cardiovascular disease prevention and control*. Geneva: World Health Organization; 2011.
2. *World health statistics 2014*. Geneva: World Health Organization; 2014.
3. Supriyantoro, Primadi O, Vensya S, Budijanto D, Hardhana B, F S, dkk. *Profil kesehatan indonesia tahun 2013*. Jakarta: Kementerian Kesehatan RI; 2014.
4. *Global health observatory map gallery*. 2011
5. Srisawasdi P, Chaloeysup S, Teerajetgul Y, Pocathikorn A, Sukasem C, Vanavanan S, et al. *Estimation of plasma small dense ldl cholesterol from classic lipid measures. American journal of clinical pathology*. 2011;136:20-29
6. Sharma SB, Garg S. *Small dense ldl: Risk factor for coronary artery disease (cad) and its therapeutic modulation. Indian J Biochem Biophys*. 2012;49:77-85
7. Stone NJ, Robinson J, Lichtenstein AH, Merz CN, Blum CB, Eckel RH, et al. *2013 acc/aha guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the american college of cardiology/american heart association task force on practice guidelines. Circulation*. 2013;129:S1-45
8. Lamarche B, Tchernof A, Moorjani S, Cantin B, Dagenais GR, Lupien PJ, et al. *Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the quebec cardiovascular study. Circulation*. 1997;95:69-75
9. Yulissa F. Pengaruh pemberian daging buah durian (*Durio zibethinus L.*) terhadap kadar profil lipid darah sukarelawan sehat [skripsi]. Medan (Indonesia): Universitas Sumatra Utara; 2013: 8-20.
10. Sulastri D, Rahayuningsih S. Pola asupan lemak, serat, dan antioksidan, serta hubungannya dengan profil lipid pada laki-laki etnik minangkabau. *Maj Kedokt Indon* [internet]. 2005 [cited 2015 Dec 13]; 55(2): 61–6. Available from: <http://mki.idionline.org>
11. Kementerian Kesehatan Republik Indonesia. *Studi diet total : potret pola makan penduduk indonesia saat ini* [internet]. 2015 [cited 2016 Jan 3]. Available from: www.depkes.go.id
12. Fernandez ML, Jimenez MV. *Associations between carbohydrate intake and risk for coronary heart disease, insulin resistance and the metabolic syndrome. In: Landlow MV, editor. Trends in dietary carbohydrates research*. Mexico: Nova Science Publishers Inc; 2006: 55–70.
13. Kasim-Karakas S, Lane E, Almario R, Mueller W, Walzem R. *Effects of dietary fat restriction on particle size of plasma lipoproteins in postmenopausal women. PubMed* [internet]. 1997 [cited 2016 Jan 7]; 46(4): 431–6. Available from: Pubmed.
14. Sugiri, Noventi S, Hisatome I, Udin B. *Carbohydrate diet links to higher risk of significant coronary artery disease in young Indonesian patients: Cardiometabolic Investigation study. Biomedical Research*. 2012; 23: 159

15. Raeini-Sarjaz M, Vanstone CA, Papamandjaris AA, Wykes LJ, Jones PJ. *Comparison of the effect of dietary fat restriction with that of energy restriction on human lipid metabolism*. Am J Clin Nutr [internet]. 2001 [cited 2016 Jan 9]; 73(2): 262–7. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/11157322>
16. Rini DRS. Hubungan asupan karbohidrat dan lemak dengan kadar profil lipid pada pasien jantung koroner rawat jalan di RSUD Dr. Moewardi Surakarta [skripsi]. Surakarta (Indonesia): Universitas Muhamadiyah Surakarta; 2015: 47
17. Supriyono M. Faktor-faktor risiko yang berpengaruh terhadap kejadian penyakit jantung koroner pada kelompok usia < 45 tahun [thesis]. Semarang (Indonesia): Universitas Diponegoro; 2008: 23.
18. Kusmana D, Moechtar H. Buku Ajar Kardiologi: Patofisiologi penyakit jantung koroner. Jakarta: Fakultas Kedokteran Universitas Indonesia; 2001: 159-79
19. Hendromartono, Tjokroprawiro A, Sutjahjo A, Pranoto A, Murtiwi S AS. Dislipidemia. Buku Ajar Ilmu Penyakit Dalam. Tjokroprawiro A, Setiawan B, Pranoto A, Nasronudin, Santoso D, editor. Surabaya: Airlangga University Press; 2007: 93-106.
20. Shahab A. Komplikasi kronik DM : penyakit jantung koroner. Sudoyo AW, Setiyohadi B, Alwi I, Simadibrata M, Setiati S E, editor. Buku Ajar Ilmu Penyakit Dalam. 5th ed. Jakarta: Interna Publishing; 2009. 120-34
21. Gray HH, Dawkins KD, Morgan JM, Simpson I. *Lecture notes cardiology*. Edisi keempat. Jakarta: Erlangga Medical Series; 2002: 107-50.
22. Anis. Waspada ancaman penyakit tidak menular, solusi pencegahan dari aspek perilaku & lingkungan. Jakarta: PT Elex Media Komputindo; 2006: 53-65.
23. Fuster V, Moreno PR, Fayad ZA, Corti R, Badimon JJ. *Atherothrombosis and high-risk plaque: Part i: Evolving concepts*. *Journal of the American College of Cardiology*. 2005;46:937-954
24. Sary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W, et al. *A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis*. *Circulation*. 1995;92:1355-1374
25. Sary HC. *Natural history and histological classification of atherosclerotic lesions an update*. *Arteriosclerosis, thrombosis, and vascular biology*. 2000;20:1177-1178
26. Rahman A. Angina pectoris stabil. In: Sudoyo AW, Setiyohadi B, Alwi I, Simadibrata M SS, editor. Buku Ajar Ilmu Penyakit Dalam. Edisi kelima. Jakarta: Interna Publishing; 2009: 1735–40
27. DiCarli, Maercelo F. *Circulation: Cardiovascular Imaging*. 2011;4:e10-6
28. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al. *Heart disease and stroke statistics--2014 update: A report from the american heart association*. *Circulation*. 2014;129:e28-e292
29. Adam JM, Soegondo S. Petunjuk praktis penatalaksanaan dislipidemia. 2004
30. Frederickson DS, Lee RS. *A system for phenotyping hyperlipoproteinemia*. *Circulation*. 1965;31:321-327

31. Olson RE. *Discovery of the lipoproteins, their role in fat transport and their significance as risk factors.* *J Nutr.* 1998;128:439S-443S
32. Ballantyne CM. *Clinical lipidology : A companion to braunwald's heart disease.* Philadelphia, PA: Saunders/Elsevier; 2009.
33. Dayspring TD, Pokrywka G. *Impact of triglycerides on lipid and lipoprotein biology in women.* *Gen Med.* 2010;7:189-205
34. Ridker PM. Ldl cholesterol: *Controversies and future therapeutic directions.* *The Lancet.* 2014;384:607-617
35. Otvos J. *Measurement of trigly ceride-rich lipoproteins by nuclear magnetic resonance spectroscopy.* *Clin.Cardiol.* 1999;22:II-21-27
36. Willerson JT. *Cardiovascular medicine.* London: Springer; 2007.
37. Mudd JO, Borlaug BA, Johnston PV, Kral BG, Rouf R, Blumenthal RS, et al. *Beyond low-density lipoprotein cholesterol: Defining the role of low-density lipoprotein heterogeneity in coronary artery disease.* *Journal of the American College of Cardiology.* 2007;50:1735-1741
38. Sniderman AD, Blank D, Zakarian R, Bergeron J, Frohlich J. *Triglycerides and small dense ldl: The twin achilles heels of the friedewald formula.* *Clinical Biochemistry.* 2003;36:499-504
39. Berneis K, Rizzo M. *Ldl size: Does it matter?* *Swiss Med Wkly.* 2004;134:720-724
40. Mora S, Szklo M, Otvos JD, Greenland P, Psaty BM, Goff DC, Jr., et al. *Ldl particle subclasses, ldl particle size, and carotid atherosclerosis in the multi-ethnic study of atherosclerosis (mesa).* *Atherosclerosis.* 2007;192:211-217
41. Rizzo M, Pernice V, Frasheri A, Di Lorenzo G, Rini GB, Spinass GA, et al. *Small, dense low-density lipoproteins (ldl) are predictors of cardio- and cerebro-vascular events in subjects with the metabolic syndrome.* *Clin Endocrinol (Oxf).* 2009;70:870-875
42. Shoji T, Hatsuda S, Tsuchikura S, Shinohara K, Kimoto E, Koyama H, et al. *Small dense low-density lipoprotein cholesterol concentration and carotid atherosclerosis.* *Atherosclerosis.* 2009;202:582-588
43. Williams PT, Zhao XQ, Marcovina SM, Brown BG, Krauss RM. *Levels of cholesterol in small ldl particles predict atherosclerosis progression and incident chd in the hdl-atherosclerosis treatment study (hats).* *PLoS One.* 2013;8:e56782
44. Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howard BV, Stein JH, et al. *Lipoprotein management in patients with cardiometabolic risk: Consensus conference report from the american diabetes association and the american college of cardiology foundation.* *Journal of the American College of Cardiology.* 2008;51:1512-1524
45. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, et al. *Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia.* *The New England journal of medicine.* 1995;333:1301-1307
46. Pedersen TR, Kjeldhus J, Berg K, Haghfeld T, Thorgeirsson G, Miettinen T, et al. *Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The scandinavian simvastatin survival study (s4).* *Lancet.* 1994;344:1383-1389

47. Tonkin A, Simes RJ. *Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The long - term intervention with pravastatin in ischaemic disease (lipid) study group *. The New England journal of medicine.* 1998;339:1349-1357
48. Meade T, Sleight P, Collins R, Armitage J, Parish S, Peto R, et al. *Mrc/bhf heart protection study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: A randomised placebo controlled trial.* *Lancet.* 2002;360:7-22
49. Hirano T, Ito Y, Koba S, Toyoda M, Ikejiri A, Saegusa H, et al. *Clinical significance of small dense low-density lipoprotein cholesterol levels determined by the simple precipitation method.* *Arteriosclerosis, thrombosis, and vascular biology.* 2004;24:558-563
50. *Measurement of small low-density lipoprotein (ldl) particles and concentration of ldl particles in cardiac risk assessment and management. Blue cross and blue shield of montana association medical policy reference manual.* 2013
51. El Harchaoui K, van der Steeg WA, Stroes ES, Kuivenhoven JA, Otvos JD, Wareham NJ, et al. *Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: The epic-norfolk prospective population study.* *Journal of the American College of Cardiology.* 2007;49:547-553
52. Freedman DS, Otvos JD, Jeyarajah EJ, Shalaurova I, Cupples LA, Parise H, et al. *Sex and age differences in lipoprotein subclasses measured by nuclear magnetic resonance spectroscopy: The framingham study.* *Clin Chem.* 2004;50:1189-1200
53. Kuller L. *Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study.* *Arteriosclerosis, thrombosis, and vascular biology.* 2002;22:1175-1180
54. Benton JL, Blumenthal RS, Becker DM, Yanek LR, Moy TF, Post W. *Predictors of low-density lipoprotein particle size in a high-risk african-american population.* *The American journal of cardiology.* 2005;95:1320-1323
55. Mora S, Otvos JD, Rifai N, Rosenson RS, Buring JE, Ridker PM. *Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women.* *Circulation.* 2009;119:931-939
56. Kathiresan S, Otvos JD, Sullivan LM, Keyes MJ, Schaefer EJ, Wilson PW, et al. *Increased small low-density lipoprotein particle number: A prominent feature of the metabolic syndrome in the framingham heart study.* *Circulation.* 2006;113:20-29
57. Wiyono A, Sugiri, Nugroho AN. *Korelasi antara small dense low density lipoprotein dengan profil lipid konvensional pada pasien penyakit jantung koroner.* 2015. *Unpublished*
58. Salman Khan M. *Small dense ldl: New marker for cardiovascular risk assessment and its therapeutic inflection.* *Biochemistry & Analytical Biochemistry.* 2012;01

59. Sacks FM, Campos H. *Clinical review 163: Cardiovascular endocrinology: Low-density lipoprotein size and cardiovascular disease: A reappraisal. J Clin Endocrinol Metab.* 2003;88:4525-4532
60. Fukushima Y, Hirayama S, Ueno T, Dohi T, Miyazaki T, Ohmura H, et al. *Small dense ldl cholesterol is a robust therapeutic marker of statin treatment in patients with acute coronary syndrome and metabolic syndrome. Clinica chimica acta; international journal of clinical chemistry.* 2011;412:1423-1427
61. Bahadir MA, Oguz A, Uzunlulu M, Bahadir O. *Effects of different statin treatments on small dense low-density lipoprotein in patients with metabolic syndrome. J Atheroscler Thromb.* 2009;16:684-690
62. Takagi H, Niwa M, Mizuno Y, Yamamoto H, Goto SN, Umemoto T. *Effects of rosuvastatin versus atorvastatin on small dense low-density lipoprotein: A meta-analysis of randomized trials. Heart Vessels.* 2014;29:287-299
63. Kim YK, Seo HS, Lee EM, Na JO, Choi CU, Lim HE, et al. *Association of hypertension with small, dense low-density lipoprotein in patients without metabolic syndrome. J Hum Hypertens.* 2012;26:670-676
64. Yazdandoust S, Parizadeh SM, Moohebbati M, Yaghmaei P, Rahsepar AA, Tavallaie S, et al. *Serum small dense low-density lipoprotein concentrations are elevated in patients with significant coronary artery stenosis and are related to features of the metabolic syndrome. Lipids.* 2012;47:963-972
65. Naganuma R, Sakurai M, Miura K, Yoshita K, Morikawa Y, Kido T, et al. *Relation of long-term body weight change to change in lipoprotein particle size in japanese men and women: The intermap toyama study. Atherosclerosis.* 2009;206:282-286
66. Rizzo M, Berneis K. *Should we measure routinely the ldl peak particle size? Int J Cardiol.* 2006;107:166-170
67. Feingold KR, Grunfeld C, Pang M, Doerrler W, Krauss RM. *Ldl subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetes. Arteriosclerosis, thrombosis, and vascular biology.* 1992;12:1496-1502
68. De Graaf J, Hak-Lemmers HL, Hectors MP, Demacker PN, Hendriks JC, Stalenhoef AF. *Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arteriosclerosis, thrombosis, and vascular biology.* 1991;11:298-306
69. Carmena R, Duriez P, Fruchart JC. *Atherogenic lipoprotein particles in atherosclerosis. Circulation.* 2004;109:III2-7
70. Liu ML, Ylitalo K, Vakkilainen J, Nuotio I, Valkonen M, Lahdenpera S, et al. *Susceptibility of ldl to oxidation in vitro and antioxidant capacity in familial combined hyperlipidemia: Comparison of patients with different lipid phenotypes. Ann Med.* 2002;34:48-54
71. Ai M, Otokozawa S, Asztalos BF, Ito Y, Nakajima K, White CC, et al. *Small dense ldl cholesterol and coronary heart disease: Results from the framingham offspring study. Clin Chem.* 2010;56:967-976
72. Mikhailidis DP, Elisaf M, Rizzo M, Berneis K, Griffin B, Zambon A, et al. *"European panel on low density lipoprotein (ldl) subclasses": A*

- statement on the pathophysiology, atherogenicity and clinical significance of ldl subclasses. Curr Vasc Pharmacol.* 2011;9:533-571
73. Koba S, Hirano T, Yoshino G, Sakai K, Sakaue T, Adachi M, et al. Remarkably high prevalence of small dense low-density lipoprotein in japanese men with coronary artery disease irrespective of the presence of diabetes. *Atherosclerosis.* 2002;160:249-256
 74. Williams PT. Smallest ldl particles are most strongly related to coronary disease progression in men. *Arteriosclerosis, thrombosis, and vascular biology.* 2003;23:314-321
 75. Mackey RH, Kuller LH, Sutton-Tyrrell K, Evans RW, Holubkov R, Matthews KA. Lipoprotein subclasses and coronary artery calcium in postmenopausal women from the healthy women study. *The American journal of cardiology.* 2002;90:71i-76i
 76. St-Pierre AC, Cantin B, Dagenais GR, Mauriege P, Bernard PM, Despres JP, et al. Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the quebec cardiovascular study. *Arteriosclerosis, thrombosis, and vascular biology.* 2005;25:553-559
 77. Arai H, Kokubo Y, Watanabe M, Sawamura T, Ito Y, Minagawa A, et al. Small dense low-density lipoproteins cholesterol can predict incident cardiovascular disease in an urban japanese cohort: The suite study. *J Atheroscler Thromb.* 2013;20:195-203
 78. Wilkins LW. Ilmu gizi menjadi sangat mudah (*nutrition made incredibly easy*). Edisi kedua. Dwijayanti L, Nugroho AW, Santoso N, editors. Jakarta: EGC; 2007: 56-69.
 79. Wardlaw GM, Smith AM. *Contemporary nutrition.* United States of America: Mc Graw Hill Companies; 2009: 120-34.
 80. Almatsier S. Prinsip dasar ilmu gizi. Jakarta: PT. Gramedia Pustaka Utama; 2001:28-47.
 81. Hutagalung H. Karbohidrat. Medan (Indonesia): Universitas Sumatra Utara. 2004;1-13.
 82. Sugiri. *High refined carbohydrate intake play role as important coronary artery disease risk factor. How can it be?. Unpublished.* Asmiha. 2013
 83. Parks EJ, Hellerstein MK. *Carbohydrate-induced hypertriacylglycerolemia: historical perspective and review of biological mechanisms.* *Am J Clin Nutr.* 2000;71:412-33
 84. Nugroho HSW. Metabolisme karbohidrat, lipid, dan protein [Internet]. 2015 [cited 2016 Jan 3]. Available from: <http://dokumen.tips/documents/m-etabolisme-karbohidratlemak-dan-protein.html>
 85. Gibson RS. *Principles of nutritional assessment.* New York: University of Michigan Press; 2005:127-74.
 86. Nyoman D, Bakri B, Fajar I. Penilaian status gizi. Jakarta: EGC; 2001: 21-39.
 87. Dahlan MS. Pintu gerbang memahami statistika, metodologi, dan epidemiologi. Jakarta: Sagung Seto; 2014: 99-107,170-17.
 88. Sastroasmoro S, Ismael S. Dasar-dasar metodologi penelitian klinis. Edisi kelima. Jakarta: Sagung Seto; 2014: 324-46
 89. McManus DD, Gore J, Goldberg RJ. Recent trends in the incidence,

- treatment, and outcomes of patients with ST and Non-ST segment acute myocardial infarction. *Am J Med.* 2011 Jan; 124(1): 40-7
90. Adar SE, Sinai T, Yosefy C, Henkin Y. Nutritional recommendations for cardiovascular disease prevention. *Nutrients.* 2013; 5:3646-83
 91. Sacks FM, Lichtenstein AH, WU JHY, Appel LJ, Creager MA, Etherton PM, et al. Dietary fats and cardiovascular disease: a presidential advisory from the American Heart Association. *Circulation.* 2017; 135:00
 92. Mozaffarian D. Dietary and policy priorities for cardiovascular disease, diabetes, and obesity: a comprehensive review. *Circulation.* 2016; 133: 187-225
 93. Hu FB. Are refined carbohydrates worse than saturated fat?. *Am J Clin Nutr.* 2010; 91: 1541-2